Abstract
The purpose of this work is to evaluate if the coffee-associated malabsorption of tablet levothyroxine (l-T4) is reduced by soft gel capsule. We recruited 8 patients with coffee-associated l-T4 malabsorption including one hypothyroid patient. For 6 months, the patients were switched to the capsule maintaining the l-T4 daily dose. Patients took the capsule with water, having coffee 1 h later (proper habit, PH) on days 1–90, or with coffee ≤5 min later (improper habit, IH) on days 91–180. After 6 months, 2 patients volunteered for an acute loading test of 600 μg l-T4 (capsule) ingested with water (PH) or with coffee (IH). In the single hypothyroid patient, the post-switch TSH ranged 0.06–0.16 mU/L (PH) versus 5.8–22.4 mU/L pre-switch (PH) and 0.025–0.29 mU/L (IH) versus 26–34 mU/L pre-switch (IH). In the other 7 patients, post-switch TSH was 0.41 ± 0.46 (PH) versus 0.28 ± 0.20 pre-switch (PH) (P = 0.61) and 0.34 ± 0.30 (IH) versus 1.23 ± 1.47 pre-switch (IH) (P < 0.001). Importantly, TSH levels in PH versus IH habit did not differ post-switch (P = 0.90), but they did pre-switch (P < 0.0001). The proportions of post-switch TSH levels <0.10 mU/L with PH (33.3 %) or with IH (33.3 %) were borderline significantly greater than the corresponding pre-switch levels with PH (10.3 %) (P = 0.088) or with IH (0 %) (P = 0.0096). In the two volunteers, the l-T4 loading test showed that coffee influenced l-T4 pharmacokinetics minimally. Soft gel capsules can be used in patients who are unable/unwilling to change their IH of taking l-T4.
Similar content being viewed by others
References
http://www.drugs.com/top200_units.html (2012). Accessed 11 Jan 2012
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)
N.R. Rose, I.R. Mackay, The Autoimmune Diseases, 3rd edn (1998). http://www.wrongdiagnosis.com/h/hypothyroidism/prevalence-types.htm. Accessed 11 Jan 2012
http://www.wrongdiagnosis.com/h/hypothyroidism/prevalence-types.htm. Accessed 11 Jan 2012
M.J. Vanderpump, The epidemiology of thyroid diseases, in Werner and Ingbar’s The Thyroid. A fundamental and Clinical Text, vol. 9, ed. by L.E. Braverman, R.D. Utiger (Lippincott Williams & Wilkins, Philadelphia, 2005), pp. 398–406
S. Benvenga, F. Trimarchi, Changed presentation of Hashimoto’s thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid 18, 429–441 (2008)
L. Santarpia, M. Valenzise, G. Di Pasquale, T. Arrigo, G. San Martino, M.P. Cicciò, F. Trimarchi, F. De Luca, S. Benvenga, TTF2/FOXE1 gene polymorphisms in Sicilian patients with permanent primary congenital hypothyroidism. J. Endocrinol. Investig. 30, 13–19 (2007)
G. Van Vliet, Hypothyroidsm in infants and children: congenital hypothyroidism, in Werner and Ingbar’s The Thyroid. A Fundamental and Clinical Text, vol. 9, ed. by L.E. Braverman, R.D. Utiger (Lippincott Williams & Wilkins, Philadelphia, 2005), pp. 1033–1041
M.J. Lamson, C.L. Pamplin, R.L. Rolleri, I. Klein, Quantitation of a substantial reduction in levothyroxine (T4) absorption by food. Thyroid 14, 876 (2004)
T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)
S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249–253 (1995)
L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)
D. Collins, R. Wilcox, M. Nathan, R. Zubarik, Celiac disease and hypothyroidism. Am. J. Med. 125, 278–282 (2012)
C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–E422 (2012)
R. Padwal, D. Brocks, A.M. Sharma, A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes. Rev. 11, 41–50 (2010)
A. Tönjes, S. Karger, C.A. Koch, R. Paschke, A. Tannapfel, M. Stumvoll, D. Fuhrer, Impaired enteral levothyroxine absorption in hypothyroidism refractory to oral therapy after thyroid ablation for papillary thyroid cancer: case report and kinetic studies. Thyroid 16, 1047–1051 (2006)
L. Anderson, F. Joseph, N. Goenka, V. Patel, Isolated thyroxine malabsorption treated with intramuscular thyroxine injections. Am. J. Med. Sci. 337, 150–152 (2009)
S. Benvenga, L. Bartolone, M.A. Pappalardo, A. Russo, D. Lapa, G. Giorgianni, G. Saraceno, F. Trimarchi, Altered intestinal absorption of l-thyroxine caused by coffee. Thyroid 18, 293–301 (2008)
A. Sindoni, R. Vita, S. Fusco, G. Saraceno, M.A. Pappalardo, O.R. Cotta, S. Grasso, F. Trimarchi, S. Benvenga, Case report. Coffee impairs intestinal absorption of levothyroxine: report of additional cases. Hot Thyroidol. HT05/09, April 2009 (http://www.hotthyroidology.com)
http://thyroid.about.com/b/2008/09/03/coffee-thyroid-drugs.htm. Accessed 11 Jan 2012
P. Colucci, P. D’Angelo, G. Mautone, C. Scarsi, M.P. Ducharme, Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther. Drug Monit. 33, 355–361 (2011)
http://www.torrefazionebugella.it/numeri.html. Accessed 11 Jan 2012
http://caffeamodomio.com/il-caffe-e-la-sua-storia/diffusione-in-italia-e-nel-mondo/il-mercato-del-caffe-e-il-suo-ruolo-nel-mondo/. Accessed 11 Jan 2012
http://www.italyecipes.com/ricette/rubriche/dettaglio_rubrica_ita.asp?index=15&titolo=NERO%20E%20BOLLENTE:%20IL%20CAFFE%27. Accessed 11 Jan 2012
T.H. Collet, J. Gussekloo, D.C. Bauer, W.P. den Elzen, A.R. Cappola, P. Balmer, G. Iervasi, B.O. Asvold, J.A. Sgarbi, H. Völzke, B. Gencer, R.M. Maciel, S. Molinaro, A. Bremner, R.N. Luben, P. Maisonneuve, J. Cornuz, A.B. Newman, K.T. Khaw, R.G. Westendorp, J.A. Franklyn, E. Vittinghoff, J.P. Walsh, N. Rodondi, The thyroid studies collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012)
G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, A. Giustina, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46, 747–751 (2010)
M.P. Ducharme, S. Benvenga, Comparison of the intestinal absorption of levothyroxine (LT4): tablet versus soft gel capsule formulation. Endocr. Rev. 32, P3–P625 (2011)
Conflict of interest
IBSA Institut Biochimique SA (Lugano, Switzerland) furnished the principal investigator (S.B.) with the capsules for the entire duration of the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vita, R., Saraceno, G., Trimarchi, F. et al. A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013). https://doi.org/10.1007/s12020-012-9772-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9772-2